北京脚后跟疼痛风济南手得了痛风怎么治疗,济南痛风病都什么不能吃,北京痛风能吃生花生吗,山东尿酸有点偏高要不要紧,山东小的痛风石可以自己消除吗,北京高尿酸是什么意思,山东痛风患者可以吃哪些蔬菜

BEIJING, Aug. 12 (Xinhuanet) -- A Connecticut woman who was savagely attacked by a pet chimpanzee and had her face deformed in 2009 was shown on TV with a new face Thursday.TV pictures revealed Charla Nash’s new nose, lips and eyelid, which were transplanted in May by doctors at the Brigham and Women’s Hospital in Boston.Nash said to the viewers that she can move her mouth, smile and smell. Her daughter Brianna added that her mother can even talk and eat better now.Dr. Bohdan Pomanhac led a 30-member surgical team to complete the face transplant in 20 hours. The team also transplanted two hands but these were later removed due to blood flow problem when Nash suffered pneumonia.Nash’s friend Sandra Herold owned a 15-year-old chimpanzee named Travis that attacked without any provocation when Nash was visiting Herold.Travis simply went berserk and could not be stopped even after Herold stabbed it with a kitchen knife. It would only let go of Nash after the police arrived and shot it dead.

WASHINGTON, June 14 (Xinhua) -- Eating a low-carbohydrate, high- protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published Tuesday in Cancer Research, a journal of the American Association for Cancer Research.The study was conducted in mice, but the scientists involved agree that the strong biological findings are definitive enough that an effect in humans can be considered."This shows that something as simple as a change in diet can have an impact on cancer risk," said lead researcher Gerald Krystal, a scientist at the British Columbia Cancer Research Center.Krystal and his colleagues implanted various strains of mice with human tumor cells or with mouse tumor cells and assigned them to one of two diets. The first diet, a typical Western diet, contained about 55 percent carbohydrate, 23 percent protein and 22 percent fat. The second, which is somewhat like a South Beach diet but higher in protein, contained 15 percent carbohydrate, 58 percent protein and 26 percent fat. They found that the tumor cells grew consistently slower on the second diet.As well, mice genetically predisposed to breast cancer were put on these two diets and almost half of them on the Western diet developed breast cancer within their first year of life while none on the low-carbohydrate, high-protein diet did. Interestingly, only one on the Western diet reached a normal life span ( approximately 2 years), with 70 percent of them dying from cancer while only 30 percent of those on the low-carbohydrate diet developed cancer and more than half these mice reached or exceeded their normal life span.Krystal and colleagues also tested the effect of an mTOR inhibitor, which inhibits cell growth, and a COX-2 inhibitor, which reduces inflammation, on tumor development, and found these agents had an additive effect in the mice fed the low-carbohydrate, high-protein diet.When asked to speculate on the biological mechanism, Krystal said that tumor cells, unlike normal cells, need significantly more glucose to grow and thrive. Restricting carbohydrate intake can significantly limit blood glucose and insulin, a hormone that has been shown in many independent studies to promote tumor growth in both humans and mice.Furthermore, a low-carbohydrate, high-protein diet has the potential to both boost the ability of the immune system to kill cancer cells and prevent obesity, which leads to chronic inflammation and cancer.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

PARIS, Sept. 21 (Xinhua) -- European heavy-lift launcher Ariane 5 lifted off two communication satellites Wednesday from the Kourou launch centre in French Guiana, live broadcast of the launching process showed.The rocket, carrying the two communication satellites Arabsat 5C and SES-2, was launched at GMT 2138.This was the fifth heavy-lift mission of Ariane 5 in 2011. Arianespace had planned six Ariane 5 missions through 2011.The satellite Arabsat-5C was developed for the Arab Satellite Communications Organization (Arabsat) to provide satellite capacity in both C-band and Ka-band frequencies for a wide range of communications services.Jointly produced by Europe's EADS Astrium and Thales Alenia Space, it will be positioned at 20 degree East orbital location to cover the Middle East and Africa.Manufactured by Orbital Sciences Corporation of the United States, SES-2 will join the fleet of European satellite telecommunications operator SES, and is to be positioned at 87 degree West for coverage over North America and the Caribbean.Both Arabsat-5C and SES-2 have life-spans as long as 15 years.This Ariane 5 dual-passenger mission was postponed from Tuesday due to local strikes of French Guiana workers.Founded in 1980 as the world's first launch service and solutions company, Arianespace planned to achieve six Ariane 5 missions through 2011. Through 2010, heavy-lift workhorse Ariane 5 finished six missions, sending a dozen spacecraft into expected orbits.The next mission from Arianespace centre in Kourou was scheduled for Oct. 20 by medium-lift vehicle Soyuz. It will be Soyuz' first mission from French Guiana with a pair of satellites for Europe's Galileo satellite navigation system.